Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Refractory Osteosarcoma: early-phase trial registry

4 of 8 indexed Refractory Osteosarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Refractory Osteosarcoma: 8 US clinical trials tracked, 4 recruiting.

Refractory Osteosarcoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition refractory-osteosarcoma

OPEN 4 | RECR 50% | LATE 0 | EARLY 8 | RANK #2176 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Refractory Osteosarcoma (thi…50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Refractory Osteosarcoma

Refractory Osteosarcoma lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Refractory Osteosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Refractory Osteosarcoma is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Refractory Osteosarcoma research.

    M.D. Anderson Cancer Center accounts for 3 of 8 trials (37.5%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Refractory Osteosarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 8 trials that report a genuine target (sentinel values excluded). 8 of those (100%) plan for fewer than 100 participants.

  4. Refractory Osteosarcoma research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 22

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Top Sponsors

M.D. Anderson Cancer Center 3 trials
Emory University 2 trials
Children's Oncology Group 1 trials
Dana-Farber Cancer Institute 1 trials
Fred Hutchinson Cancer Center 1 trials

Named interventions

Most-linked intervention names on Refractory Osteosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cabozantinib Drug
2 trials
Gemcitabine Drug
2 trials
Cyclophosphamide Drug
2 trials
Myeloid growth factor Drug
1 trials
Pepinemab Biological
1 trials
Pharmacological Study Other
1 trials
Oleclumab Biological
1 trials
Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate Combination
1 trials

US sites by state

Facility locations filed on Refractory Osteosarcoma trials. A trial with sites in several states counts in each.

Texas 3 trials
Georgia 3 trials
Massachusetts 2 trials
Washington 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Refractory Osteosarcoma page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Osteosarcoma condition card totals 8 registered trials; most-linked intervention Cabozantinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.